Related Experiment Videos
Urologic applications of botulinum toxin therapy for voiding dysfunction.
Raymond Rackley1, Joseph Abdelmalak
1Section of Voiding Dysfunction and Female Urology, Glickman Urological Institute, Cleveland Clinic Foundation, A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA. RackleR@ccf.org.
Current Urology Reports
|October 6, 2004
Summary
Botulinum toxin type-A is a minimally invasive treatment for various bladder dysfunctions. This therapy offers selective, reversible muscle weakness for conditions like overactive bladder and interstitial cystitis.
Area of Science:
- Urology
- Neurology
- Pharmacology
Background:
- Botulinum toxin is a presynaptic neuromuscular blocking agent.
- It induces selective and reversible muscle weakness.
- Botulinum toxin type-A is widely used for spasticity syndromes in adults and children.
Purpose of the Study:
- To provide an overview of the urologic adoption of botulinum toxin therapy.
- To discuss its application in treating lower urinary tract dysfunctions.
Main Methods:
- Review of the clinical adoption and application of botulinum toxin type-A.
- Focus on its use in urologic conditions.
Main Results:
- Botulinum toxin type-A has been adopted for treating idiopathic and neurogenic detrusor overactivity.
- It is also used for interstitial cystitis, detrusor-sphincter dyssynergia, urinary retention, and prostatic conditions.
Conclusions:
- Botulinum toxin type-A is a valuable minimally invasive therapy for diverse lower urinary tract dysfunctions.
- Its application in urology continues to expand for various conditions.